Menlo Park, California, July 5, 2015. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology and infectious diseases, announced today that it will present at the 2015 Wedbush PacGrow Healthcare Conference in New York, NY. Merdad Parsey, Chief Executive Officer, is scheduled to present on Wednesday, August 12th at 1:55p.m. ET.
About 3-V Biosciences
3-V Biosciences, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics in oncology and virology based on expertise in lipid biology. The company’s lead oncology product candidate is a first-in-class inhibitor of fatty acid synthase (FASN) currently being evaluated in a Phase 1 clinical trial for the treatment of solid tumors. Lipids are integral to cellular metabolism, cellular signaling and cellular structure and the emerging understanding of lipid biology opens up promising new areas for drug development. Together with a group of world-renowned experts in lipid biology, we have established expertise to translate this biology into patient benefit with a focus on oncology and virology drug development. The company is located in Menlo Park, California.
Investor Relations Contact:
Jamien Jones
Blueprint Life Science Group
Telephone: 415.375.3340 Ext. 103
jjones@bplifescience.com
